BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1438 related articles for article (PubMed ID: 18439766)

  • 1. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
    Douillard JY; Rosell R; De Lena M; Riggi M; Hurteloup P; Mahe MA;
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):695-701. PubMed ID: 18439766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
    Bennouna J; Senellart H; Hiret S; Vaissiere N; Douillard JY
    Lung Cancer; 2011 Oct; 74(1):30-4. PubMed ID: 21371774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
    Keller SM; Adak S; Wagner H; Herskovic A; Komaki R; Brooks BJ; Perry MC; Livingston RB; Johnson DH
    N Engl J Med; 2000 Oct; 343(17):1217-22. PubMed ID: 11071672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.
    Pisters KM; Evans WK; Azzoli CG; Kris MG; Smith CA; Desch CE; Somerfield MR; Brouwers MC; Darling G; Ellis PM; Gaspar LE; Pass HI; Spigel DR; Strawn JR; Ung YC; Shepherd FA; ;
    J Clin Oncol; 2007 Dec; 25(34):5506-18. PubMed ID: 17954710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
    Johnson BE; Rabin MS
    Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5022s-5026s. PubMed ID: 16000607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.
    Wakelee HA; Stephenson P; Keller SM; Wagner H; Herskovic A; Komaki R; Marks RS; Perry MC; Livingston RB; Johnson DH;
    Lung Cancer; 2005 Jun; 48(3):389-97. PubMed ID: 15893008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Postoperative adjuvant therapy for 189 patients with completely resected non-small cell lung cancer of stage III(A)].
    Li Q; Gao JM; Liang PY; Xie FY; Liu GZ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1463-6. PubMed ID: 15566658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
    van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
    J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.
    Wakelee H; Dubey S; Gandara D
    Oncologist; 2007 Mar; 12(3):331-7. PubMed ID: 17405898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy.
    Bischof M; Debus J; Herfarth K; Muley T; Kappes J; Storz K; Hoffmann H
    Strahlenther Onkol; 2007 Dec; 183(12):679-84. PubMed ID: 18040612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.
    Alam N; Shepherd FA; Winton T; Graham B; Johnson D; Livingston R; Rigas J; Whitehead M; Ding K; Seymour L
    Lung Cancer; 2005 Mar; 47(3):385-94. PubMed ID: 15713522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
    Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
    Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial.
    Dunant A; Pignon JP; Le Chevalier T
    Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5017s-5021s. PubMed ID: 16000606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patients.
    Dediu M; Horvat T; Tarlea A; Anghel R; Cordos I; Miron G; Iorga P; Alexandru A; Nistor C; Grozavu C; Savu C
    Lung Cancer; 2005 Jan; 47(1):93-101. PubMed ID: 15603859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer.
    Park JH; Lee CT; Lee HW; Baek HJ; Zo JI; Shim YM
    Eur J Cardiothorac Surg; 2005 Jun; 27(6):1086-91. PubMed ID: 15896623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.
    Jaklitsch MT; Herndon JE; DeCamp MM; Richards WG; Kumar P; Krasna MJ; Green MR; Sugarbaker DJ
    J Surg Oncol; 2006 Dec; 94(7):599-606. PubMed ID: 17039491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
    Waller D; Peake MD; Stephens RJ; Gower NH; Milroy R; Parmar MK; Rudd RM; Spiro SG
    Eur J Cardiothorac Surg; 2004 Jul; 26(1):173-82. PubMed ID: 15200998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M;
    Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.